Genetically engineered cell-derived nanovesicles for cancer immunotherapy
Nanoscale · 2024
DOI: 10.1039/d3nr06565k ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nanoscale, 2024. Verfasst von Shan He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA. zhaozm@uic.edu. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Extracellular Vesicles, Genetic Engineering. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, University of Illinois at Chicago.
Abstract (Originalsprache)
The emergence of genetically engineered extracellular vesicles has marked a new epoch in cancer immunotherapy, presenting substantial clinical potentials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA. zhaozm@uic.edu.
- Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL 60612, USA.
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- University of Illinois at Chicago
Zitieren
APA
He, S., & Zhao, Z. (2024). Genetically engineered cell-derived nanovesicles for cancer immunotherapy. Nanoscale. https://doi.org/10.1039/d3nr06565k
Vancouver
He S, Zhao Z. Genetically engineered cell-derived nanovesicles for cancer immunotherapy. Nanoscale. 2024. doi:10.1039/d3nr06565k
BibTeX
@article{He2024,
author = {He, Shan and Zhao, Zongmin},
title = {Genetically engineered cell-derived nanovesicles for cancer immunotherapy},
journal = {Nanoscale},
year = {2024},
doi = {10.1039/d3nr06565k}
}
EUVIMED